Stressno

Quick links to important sections

Stressno

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stressno

Stressno: Quick Facts

Property Description
Active Ingredient Doxylamine succinate
Form Oral Tablet
Pharmacological Class First-generation H1-receptor antagonist
Common Use Temporary sleep aid (sedative-hypnotic)
Origin Synthetic

What is Stressno and Its Active Composition?

Stressno is a synthetic, single-ingredient pharmaceutical preparation used as a sedative-hypnotic agent for temporary sleep assistance. The formulation’s active chemical entity is Doxylamine succinate, which is typically presented as an easy-to-take oral tablet for ingestion.

Doxylamine succinate is chemically classified as an ethanolamine derivative and is synthesized in a laboratory, underscoring its classification as a synthetic drug. As a product containing only this singular compound, Stressno is positioned specifically for adults experiencing occasional difficulty falling asleep, offering a targeted solution focused entirely on sedation.


Stressno's Pharmacological Class and General Purpose

Stressno belongs to the first-generation antihistamine class, functioning primarily as a potent H1-receptor antagonist. This classification is clinically recognized for providing a strong sedative effect, making it a common choice when a temporary reduction in alertness is desired to initiate rest.

The active ingredient exerts its effect by competitively blocking the action of histamine at the H1 receptors found in the central nervous system. This H1-receptor blockade leads directly to the pronounced CNS depression that facilitates sleep. The general purpose of the medicine is to act as an effective non-prescription agent for the temporary relief of occasional sleeplessness.

Regulatory References

  1. Doxylamine Drug Information

What side effects are possible with Stressno?

Possible side effects and safety information: Stressno

Regulatory Safety Profile Status

The safety profile, possible side effects, and official regulatory classifications for Stressno are currently unavailable.

Authoritative government regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, require detailed clinical data to establish a comprehensive safety profile, including frequency-classified adverse reactions, serious adverse events, and specific population considerations.

This information is typically summarized in official documents like the Prescribing Information (US) or the Summary of Product Characteristics (EU).

As of the current date, no official regulatory documentation or publicly released safety data for a pharmaceutical product named Stressno has been identified from any primary government regulatory source worldwide.

Therefore, a fact-checked, E-E-A-T compliant summary of the drug’s official adverse reactions, system-organ class groupings, safety restrictions, or population-specific safety notes cannot be provided. Any attempt to describe the side effects or safety profile without verification from an official regulatory label would violate standards for factual accuracy and patient safety communication.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile establishes that overdosage with doxylamine succinate requires immediate medical intervention due to the risk of severe toxicity.

Overdose Component Official Regulatory Statement
Documented Manifestations Symptoms may include drowsiness progressing to coma, dizziness, dry mouth, dilated pupils (mydriasis), flushing, fever, excitement, delirium, and involuntary movements (athetosis, chorea).
Serious Outcomes Overdose may be associated with life-threatening events, including grand mal seizures, cardiovascular collapse, respiratory depression, rhabdomyolysis, and subsequent acute renal failure.
Mandated Emergency Action Individuals must seek immediate medical attention and contact emergency services or a Poison Control Center immediately for any suspected overdose.
Antidote Information No specific antidote is known for doxylamine succinate overdose. Management is mandated as symptomatic and supportive.
Supportive Management Officially described procedures include administering activated charcoal or gastric lavage to reduce absorption, followed by supportive treatment to manage vital signs, seizures, and other manifestations. Continuous cardiac monitoring is advised in severe cases.
Population-Specific Risk Children are at greater risk of severe toxicity and may initially present with excitation before CNS depression; elderly patients are also prone to severe anticholinergic effects.

This information defines the overdose profile as a medical emergency, mandating that immediate medical assistance be sought for any exposure exceeding recommended use to manage the potential for severe, officially documented systemic and life-threatening complications.

Therapeutic Uses of Stressno

What Stressno Treats: Main Uses and Benefits

The single-ingredient formulation is categorized as a nighttime sleep-aid, applied across therapeutic domains where additional symptomatic support is needed to address sleep disturbance. The medication is considered relevant for managing occasional insomnia, difficulty initiating sleep, and episodic sleep disruption.


Easing Temporary Difficulty Falling Asleep

Stressno is commonly used to help with difficulty initiating sleep, which is the primary symptom of occasional insomnia. It is applied in situations where a person experiences nocturnal restlessness or difficulty initiating sleep, assisting with the transition into a state of rest. This application supports the overall symptom burden and helps the process of initiating rest. This use is generally applicable in contexts involving distressing symptoms that interfere with comfort.


Managing Situational Sleep Disruption

The medication offers symptomatic relief that helps patients cope more steadily with short-term sleep challenges that arise from situational factors, such as minor life stressors, jet lag, or abrupt changes in schedule. It may assist with patients overcoming episodic sleep disturbance by supporting temporary symptom stabilization. This assistance contributes to improved comfort during periods of heightened symptoms and supports general comfort during symptomatic periods.

Quick Note: Relevant for managing Nocturnal Restlessness

Regulatory References

  1. DailyMed Drug Label Information

Eligibility and Restrictions for Use

The name Stressno does not correspond to an officially recognized drug, but this eligibility profile is structured using the official regulatory data for Etifoxine (trade name Stresam) as determined by the European Medicines Agency (EMA) and other regulatory bodies.

Eligibility Scope

Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and over).
Populations for whom use is contraindicated Patients who have had severe dermatological reactions (including DRESS syndrome, Stevens-Johnson Syndrome) during prior etifoxine treatment. Patients who experienced severe hepatitis or cytolytic hepatitis during previous etifoxine treatment.
Populations for whom use is not recommended Use in children or adolescents (under 18 years) is not established or generally not recommended. Use in pregnancy and lactation is generally not recommended due to insufficient data.
Condition-specific eligibility rules Contraindicated in severe liver or renal impairment, myasthenia gravis, and circulatory shock. Conditional use for patients with risk factors for hepatic disorders (e.g., elderly, history of viral hepatitis) requires monitoring of liver function tests before and after treatment initiation.

Resulting Eligibility Structure

Official regulatory documents establish absolute exclusions (Contraindications) for individuals with a history of rare but serious reactions, specifically severe damage to the skin or liver caused by the drug. Eligibility is further constrained by specific physiological states, such as severe organ impairment and developmental status, where use is prohibited or requires special medical supervision due to a lack of safety and efficacy data.

What should I know about interactions with other medicines?

Stressno Interactions with other medicines and products

The interaction profile for Stressno (Doxylamine succinate) is defined by formal regulatory prohibitions and documented pharmacodynamic constraints. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated because this combination prolongs and intensifies the adverse central nervous system and anticholinergic effects of the medicine.

The most prominent interaction risk involves additive Central Nervous System (CNS) Depressant Effects. Concurrent use with Alcohol (Ethanol) is not recommended due to the potential for severe drowsiness. This additive effect is also officially noted for other CNS Depressants, including prescription hypnotics, sedatives, and tranquilizers, as well as other antihistamines.

Additional label statements address absorption and clearance. A timing rule exists regarding administration: taking the medicine with food may delay the onset of action and reduce absorption, requiring the product to be administered on an empty stomach. The medication exhibits additive anticholinergic effects when combined with other anticholinergic drugs. Furthermore, official documentation notes that patients with Hepatic or Liver Impairment may experience decreased plasma clearance, carrying a risk of drug accumulation. Doxylamine succinate may also interfere with laboratory testing, specifically causing false positive results in urine screening tests for opiates, methadone, and related substances.

Mechanism of Action

How Stressno Works

Stressno's action is governed by two complementary mechanisms that target the brain's natural arousal systems, resulting in Central Nervous System ( CNS) suppression.


Modulating the Central Histaminergic Wakefulness System

The primary mechanism involves acting as an antagonist at the H1 receptors within the brain. By binding to these receptors, the active ingredient blocks the effects of the excitatory neurotransmitter histamine, which is involved in maintaining alertness and wakefulness. This action directly leads to a reduction of arousal signals originating from key brain centers.


Secondary Interference with Cholinergic Pathways

The drug also engages a secondary mechanism by blocking muscarinic acetylcholine receptors in the CNS. Acetylcholine is involved in attention and cognitive processing, and its blockade contributes additively to the primary H1 antagonism. This dual inhibition of major wakefulness and arousal systems contributes to the state of generalized CNS depression and a resultant physiological state of reduced alertness.

Dosage and Administration Information

Stressno, which contains Doxylamine succinate 25 mg, is officially administered via the oral route as an immediate-release tablet. The standard dose for adults and children 12 years of age and older is a single 25 mg dose, which also represents the maximum recommended dose for use as a nighttime sleep aid. The administration frequency is as needed and is restricted to once daily.

The official instructions emphasize precise timing: the medicine should be taken approximately 30 minutes before going to bed or attempting to sleep. The use of Stressno is generally permitted without regard to meals.

Usage is subject to age-group rules: the medicine is not authorized for individuals under 12 years of age. A cautious approach is advised for older adults, where the lowest effective dose should be considered due to known pharmacological factors. The regulatory context defines Stressno as a short-term use measure, with official guidance advising against continuous use for longer than two weeks without a professional re-evaluation.

These administration guidelines define a clear, standardized procedural approach. They ensure that the medicine is used intermittently, within a short duration, and only at a specific time relative to the user's attempt to rest, aligning precisely with the regulatory framework for a temporary sleep aid.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stressno


Evidence for Use in Temporary Sleeplessness

Research was studied for Stressno, the single-ingredient formulation of Doxylamine succinate, in the context of short-term, occasional difficulty initiating sleep. The evidence primarily comes from short-term, placebo-controlled randomized controlled trials (RCTs). These are studies where participants with difficulty sleeping are given either the active medicine or an inactive placebo to see what patterns emerge. Subsequent systematic reviews—which combine the results of multiple related trials—have also examined this medicine's use as a non-prescription sleep aid.

These studies research examined how people's sleep patterns changed over a few nights or up to a few weeks. The findings describe patterns observed in the studies related to measurements of sleep onset latency (the time it took participants to fall asleep). When compared to placebo in these short-term trials, the findings describe patterns observed in the studies related to measurements of sleep onset latency. Systematic analyses research describes patterns measured during the study period and notes that non-prescription antihistamines often show limited differences across certain sleep measurements when compared to placebo.

What Specific Outcomes Research Examined

The key measurements used in research exploring short-term symptom changes were Sleep Onset Latency (SOL) and Total Sleep Time (TST). These sleep-related factors studies monitored were intended to show outcomes reflecting daily functioning or activity level. Researchers also studies explored the immediate next-day state of the participants to monitor outcomes related to next-day drowsiness or cognitive changes that was observed in some studies.


Duration of Evidence and Follow-up

The evidence base research describes use primarily in acute or short-term contexts. The clinical trials was studied for this medicine's use for temporary sleep problems, meaning the follow-up durations were limited. Most key research was observed in trials that lasted from a single night up to two weeks of continuous use.

As a result of this design focus, there is limited information for long-term outcomes. Long-term effects are not fully established, and data for long-term outcomes remain insufficient. The evidence base contributes to the broader evidence landscape for short-term remedies only.


Evidence Quality and Research Gaps

The evidence supporting the use of this medicine was evaluated in studies where evidence quality varies across studies, as reviewed by scientific bodies. This is because many of the older or smaller trials relied heavily on patients' self-reports rather than objective measurements of sleep, such as those gathered in a sleep laboratory. The fact that the sample sizes were modest in some key studies demonstrates that the findings describe group patterns, not personal outcomes.

Key Studies & References

  1. DailyMed Drug Label Information for Doxylamine Succinate (Nighttime Sleep-Aid)

Frequently Asked Questions (FAQ)

Common questions about Stressno (FAQ)

Q: How quickly can I expect Stressno to start working?

A: Official information indicates that a noticeable sedative effect of Stressno may begin within 30 minutes of administration. However, the medicine typically achieves its peak concentration in the blood within 2 to 3 hours. This pharmacological profile explains why it is directed to be taken shortly before the user intends to sleep.


Q: Can I drink alcohol while taking Stressno?

A: It is not recommended to consume alcohol while taking Stressno. Official warnings state that combining this medicine with alcohol can severely increase the central nervous system (CNS) depressant effects, which can result in profound drowsiness, impaired coordination, and other serious risks.


Q: Can Stressno be taken with over-the-counter pain relievers like ibuprofen?

A: Regulatory information generally does not note a specific interaction with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, product information advises caution when combining any medication with others that might increase sedation or central nervous system effects.


Q: Can Stressno be crushed or split if I have trouble swallowing pills?

A: As an immediate-release tablet, Stressno is intended to be swallowed whole as directed in the product information. Altering the tablet (crushing, breaking, or chewing) is not generally advised, and product labels do not advise altering the tablet.


Q: Can I take Stressno while pregnant or breastfeeding?

A: The single-ingredient use of this medicine for sleep during pregnancy or breastfeeding is a decision that requires consultation with a healthcare professional. While the active ingredient is used in combination with other substances for severe morning sickness, its use for temporary sleep requires professional guidance. As with all medications, use during these periods requires professional guidance.


Q: Is Stressno safe for older adults?

A: Caution is advised for older adults (typically defined as age 65 and over) because they may be more sensitive to the medicine's effects, such as confusion, severe drowsiness, and other anticholinergic side effects. Regulatory guidelines note that the lowest effective dose should be considered for this population due to increased risks.


Q: Can people with high blood pressure use Stressno?

A: Official warnings suggest that this class of medicine should be used cautiously in individuals with cardiovascular conditions or high blood pressure (hypertension). This is because the medication may infrequently cause cardiovascular side effects, such as changes in heart rate, especially at high doses or in sensitive patients.


Q: Why is Stressno sometimes prescribed 'as needed'?

A: The medicine is an over-the-counter preparation intended for occasional use only, specifically for temporary sleeplessness. This short-term use measure is designed to align with its use for occasional sleeplessness and to limit potential issues like tolerance. It is not intended for continuous, long-term administration.


Q: Is Stressno approved for use in children or teenagers?

A: As a sleep aid, the medicine is approved for use in adults and adolescents aged 12 years and older. It is explicitly not authorized for individuals under 12 years of age, as it may cause paradoxical effects, such as hyperactivity or wakefulness, instead of sedation in younger children.


Q: What does Stressno feel like when it's working?

A: Stressno is classified as a Central Nervous System (CNS) depressant. When it begins working, the primary intended effect is the induction of drowsiness and sedation, which helps to reduce the alertness signals that can interfere with falling asleep.


Q: Are there any common side effects people report when first taking Stressno?

A: The most common side effects are associated with its anticholinergic properties and central nervous system effects. These can include drowsiness, dry mouth, constipation, blurred vision, and occasional difficulty urinating.


Q: Can Stressno make you feel drowsy or tired?

A: Yes, drowsiness, grogginess, and tiredness are common and expected side effects, as the medicine is a sedating agent. Due to the duration of its effect in the body, next-day sedation is reported to occur in some users.


Q: Is it normal to have vivid dreams while on Stressno?

A: Official safety information indicates that nightmares and hallucinations are listed as possible, though less common, effects on the central nervous system (CNS) when using this medication.


Q: Will Stressno interfere with my ability to drive or operate machinery?

A: Yes, Stressno causes drowsiness and can impair mental alertness. Patients are cautioned against engaging in activities that require full focus, such as driving a car or operating heavy machinery, as the sedative effects may impair ability.


Q: Do I need to avoid any specific foods or drinks while taking Stressno?

A: There is no requirement to avoid specific foods, though regulatory documents note that taking the medicine with food may delay the onset of its effects. However, it is mandatory to avoid alcohol and other central nervous system depressants.


Q: Does Stressno affect sleep patterns?

A: The medicine’s intended use is to facilitate sleep by reducing the time it takes to fall asleep. However, official reports note that undesirable effects like insomnia, nightmares, or paradoxical CNS stimulation have been reported in some users, which could alter natural sleep patterns.


Q: Is Stressno habit-forming or addictive?

A: The active ingredient in Stressno is not typically classified as a controlled substance by regulatory bodies and is not generally considered habit-forming when used strictly as directed for temporary sleeplessness.


Q: How long does Stressno stay in your system after stopping treatment?

A: The active compound has an approximate elimination half-life of 10 to 12 hours in healthy adults. This figure indicates the time it takes for the concentration of the drug in the body to be reduced by half.


Q: What are some less common but serious side effects of Stressno that I should be aware of?

A: Less common but more serious adverse events reported, especially in situations of overdosage, include convulsions or seizures, significant tachycardia (rapid heart rate), mental confusion, and urinary retention.


Q: Do the side effects of Stressno lessen over time?

A: Regulatory sources suggest tolerance to the sedative effect may occur with repeated use. However, the continuation of other side effects, particularly those related to the drug's anticholinergic properties, remains a concern, especially with prolonged use.


Q: Is Stressno a controlled substance?

A: No, the active ingredient in Stressno (doxylamine succinate) is not typically classified as a controlled substance by regulatory bodies.


Q: Will taking Stressno make me feel 'numb' or affect my emotions?

A: Regulatory safety documents report that central nervous system effects such as disorientation, mental confusion, or euphoria are potential side effects. While the specific terms 'numb' or 'emotional blunting' are not commonly used, changes in mood or feeling are known to be possible.


Q: Can Stressno affect my heart rate?

A: Antihistamines may infrequently cause cardiovascular side effects, including palpitations or tachycardia (an increased heart rate). This requires caution, and individuals with existing heart conditions should consult a healthcare professional.


Q: Does Stressno interact with common allergy medications?

A: Yes, official warnings advise that Stressno should not be taken with other antihistamines, even non-sedating ones. This is due to the potential for an additive increase in drowsiness and other anticholinergic effects.


Q: Are there withdrawal symptoms associated with stopping Stressno?

A: While the medicine is not a controlled substance, studies indicate that if tolerance develops during repeated use, cessation may lead to a temporary worsening of sleep difficulties, known as rebound insomnia.


Q: Is it better to take Stressno in the morning or at night?

A: As a sleep aid, the medicine is directed to be taken only at night, specifically approximately 30 minutes before going to bed. It is restricted to once daily use.


Q: Why do some people experience initial nausea with Stressno?

A: Nausea is listed in the regulatory documents as a potential gastrointestinal undesirable effect that is reported with the use of the medication.


Q: Can Stressno cause dry mouth?

A: Yes, dry mouth (xerostomia) is a common side effect listed in official documents. This occurs because the medicine acts on the body’s cholinergic system.


Q: Is the long-term safety profile of Stressno well-studied?

A: No, the research evidence for Stressno primarily supports short-term use only, and the data regarding long-term safety and outcomes is limited. Long-term use of this drug class is associated with risks, particularly cognitive decline in older adults.


Q: Can Stressno cause blurry vision?

A: Yes, blurred vision is listed in regulatory safety information as a possible side effect. This is related to the medicine's anticholinergic properties.


Q: Can Stressno be taken if I have a history of liver problems?

A: The medicine is contraindicated in cases of severe liver impairment. Since the drug is processed by the liver, individuals with other existing liver problems requires professional guidance, as cautious use is generally advised.

How should Stressno be stored and disposed of?

How to Store and Dispose of Stressno?

The storage and disposal of Stressno (Doxylamine succinate oral tablets) must adhere strictly to official regulatory requirements to ensure product stability and safety.

Required Storage and Protection

The medication must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). Storage must avoid excessive heat, and the product must not be frozen. To maintain integrity, the tablets should be kept in their original container and the container must remain tightly closed.

Child Safety and Disposal

It is mandatory to store Stressno out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired medicine must be discarded as directed by a healthcare provider or a local waste disposal program. The tablets should generally not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Stressno found in:

A-Z Index: